Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension-Reference-Cited by-同舟云学术

Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension

Published:2015-06-17 Issue:8 Volume:17 Page:805-808
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Amin N. B.¹,Wang X.¹,Mitchell J. R.²,Lee D. S.¹,Nucci G.¹,Rusnak J. M.¹

Affiliation:

1. Pfizer Worldwide Research and Development, Pfizer; Cambridge MA USA

2. Texas Center for Drug Development Inc; Houston TX USA

Funder

Pfizer

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12486/fullpdf

Reference11 articles.

1. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice;Cuypers;Acta Clin Belg,2013

2. Exploring newer target sodium glucose transporter 2 for the treatment of diabetes mellitus;Vaidya;Mini Rev Med Chem,2010

3. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study;Stenlof;Curr Med Res Opin,2014

4. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial;Haring;Diabetes Care,2013

5. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial;Cefalu;Lancet,2013

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials;Pharmaceuticals;2024-07-11

2. Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis;Endocrine Practice;2024-05

3. Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations;Current Hypertension Reports;2023-11-10

4. Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis;Medicine;2023-03-10

5. The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors;Expert Review of Cardiovascular Therapy;2022-12-22